This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

5 Dumbest Things on Wall Street This Week: March 15

Stocks in this article: BBY GE SKUL SPPI MCD DNKN SBUS

1. Spectrum Surrenders

There is no joy for Spectrum (SPPI - Get Report) CEO Raj Shrotriya. His mighty Fusilev has struck out.

After Tuesday's close, Spectrum Pharmaceuticals cautioned that sales of its colon cancer drug Fusilev will be $10 million to $15 million in the first quarter and $80 million to $90 million for all of 2013. By comparison, Fusilev sales were $44.6 million and $204 million in the fourth quarter and full year 2012, respectively.

Yeah, it was pretty gruesome. We haven't seen a swing and a miss that big since George Foster batted cleanup for the 1982 New York Mets.

And unfortunately for Spectrum, Fusilev is the biotech's biggest slugger, so its demise can't be made up elsewhere in the company's line-up. Total revenue for 2013 is now expected to be in the range of $160 million to $180 million compared to $268 million in 2012. Analysts, on average, were expecting Spectrum to bring home $297 million in revenue this year.

On the other hand, Spectrum's strikeout was a grand slam for the shorts, who have long been swarming all over this stock. Spectrum shares sank over 37% to $7.90 on Wednesday after closing the day before at $12.43.

The big score was especially sweet for Spectrum bears because Shrotriya has repeatedly thrown the market's equivalent of bean balls at them. In December, Shrotriya attempted to squeeze doubters out of the stock with a special cash dividend of 15 cents per share payable to the company's shareholders.

And on Feb. 21st of this year, Shrotriya really unloaded on the shorts, boasting on a conference call about Fusilev growth despite flat revenue for the past three quarters.

"Just how colossally awful is this new revenue guidance?" asks TheStreet's biotech ax Adam Feuerstein. "Just under one month ago, Spectrum CEO Raj Shrotriya promised investors more revenue growth in 2013. Tuesday, he admits first-quarter Fusilev sales will drop more than 70% sequentially. For 2013, Fusilev sales will retrench by a jaw-dropping 60%."

On the ensuing conference call Wednesday morning, Shrotriya pitched Spectrum as even more of a bargain now that Fusilev sales are stunted.

Oh man, that's an eephus ball if we ever saw one. With ridiculously weak offerings like that, we doubt the CEO best known for headhunting shortsellers will last much longer on Spectrum's mound.

In fact, we expect he'll be soon be visiting a headhunter himself. A corporate one.

-- Written by Gregg Greenberg in New York City.

Disclosure: TheStreet's editorial policy prohibits staff editors and reporters from holding positions in any individual stocks.
5 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,672.60 -141.38 -0.79%
S&P 500 2,051.82 -11.33 -0.55%
NASDAQ 4,757.8790 +7.4820 0.16%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs